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Quizalofop-p-ethyl {(R)-2-[4-(6-chloro-
quinoxalin-2-yloxy)phenoxy] propionic acid;
QpE} is a selective, postemergence phenoxy
herbicide that belongs to the chemical group
of aryloxyphenoxypropionic acids. The
aryloxyphenoxypropionic acids, together
with the cyclohexanediones class, account for
approximately 10% of the global herbicide
market (Harwood 1999). QpE is a slightly
toxic compound [U.S. Environmental
Protection Agency (EPA) toxicity class III]
and is irritating to the skin and only slightly
irritating to the eyes (U.S. EPA. 1998). We
present the ﬁrst reported case in humans of a
prolonged cholestatic/hepatocellular toxicity
induced by occupational exposure to QpE.
Case Presentation
A 75-year-old male farmer presented with a
4-day history of jaundice, with no pain, no
associated symptoms of pruritus or fever,
and no dark urine or light-colored stools.
Physical examination demonstrated jaun-
dice on the sclera (whites of the eyes) and
skin, but signs of liver dysfunction or fail-
ure were absent. The gallbladder and liver
were not palpable, and there was no ten-
derness or discomfort in the right upper
quadrant of the abdomen. No notable
findings were present upon examination of
the other systems. The patient’s medical
history revealed mild chronic obstructive
pulmonary disease; the patient was an ex-
smoker and had been treated occasionally
with inhaled bronchodilators. There was
no previous history of biliary tract disease,
alcohol abuse, drug addiction, or blood
transfusions. The patient reported that he
had used QpE to spray his crops 9 days
before admission, and he was exposed to a
large amount of the chemical.
The predominant laboratory findings
included markedly elevated serum levels of
total [15.85 mg/dL; upper limit of normal
range (ULN) = 1.0] and direct bilirubin
(13.84 mg/dL; ULN = 0.3), a 2-fold increase
in alkaline phosphatase (ALP; 217 IU/L;
ULN = 130), and a 5-fold increase in
γ-glutamyltransferase (γ-GT; 402 IU/L; ULN
= 75). Serum levels of alanine (ALT) and
aspartate aminotransferase (AST) were ele-
vated 5-fold (187 IU/L; ULN = 40), and
2-fold (71 IU/L; ULN = 40), respectively
(Figure 1). Complete blood count, hemato-
crit, platelets, serum amylase, albumin and
prothrombin time, as well as assessment of
kidney function, were all within reference
values. Serologic testing for hepatitis (A, B,
and C), cytomegalovirus, Epstein-Barr virus,
herpes simplex, and varicella zoster was nega-
tive. Diagnostic imaging was also performed:
Ultrasound of the upper abdomen did not
identify any stones or sludge in the gallblad-
der, or dilations of the intra- and extrahepatic
bile ducts. Liver and spleen size were meas-
ured within normal range.
During hospitalization the patient
remained stable, and at no time did he
develop symptoms or signs of liver failure or
decompensation. Nevertheless, his serum
bilirubin followed an ascending course,
peaking at the end of the first week
(26.51 mg/dL), whereas ALP, γ-GT, AST,
and ALT levels decreased. The patient under-
went endoscopic retrograde cholangio-
pancreatography (catheterization of Vater
ampulla was unfeasible because of its ectopic
location toward the third segment of the
duodenum); subsequently a magnetic reso-
nance cholangiopancreatogram, displayed
normal gallbladder, biliary tract, and pancrea-
tic duct anatomy. Further, clinical chemistry
for α-fetoprotein and cancer antigens was
normal. Electrophoresis of serum proteins,
and quantitation and immunoﬁxation assays
of immunoglobulins revealed no pathology.
Serum testing for antinuclear antibody,
smooth muscle antibody, anti-liver–kidney
microsome (LKM) antibody, and anti-
mitochondrial antibody was negative. In con-
trast, cytoplasmic antineutrophil cytoplasmic
antibodies (c-ANCA) and elevated serum lev-
els ofβ2-microglobulin (β2-MG = 4.66 mg/L;
ULN = 3.21) were detected.
The patient was treated with ursodeoxy-
cholic acid (UDCA) per os (750 mg/day) from
the ﬁrst day of hospitalization. Prednisolone
(intravenous dose of 37.5 mg/day) was started
after magnetic resonance cholangiopancreato-
graphy, with the most prominent diagnosis
being cholestatic/hepatocellular drug hepato-
toxicity. Finally, after the biliary tree was
assessed to have no signs of obstruction, a
percutaneous liver biopsy was performed.
Moderate portal inﬂammatory inﬁltrates con-
sisting of lymphocytes, polymorphonuclear
cells, and eosinophils (Figure 2A) plus moder-
ate cholestasis (Figure 2B), mild inflamma-
tion, and foci of necrosis in the liver lobule
were the hallmarks of the histopathologic liver
lesions, which is consistent with drug-induced
hepatotoxicity. Two weeks after his admission,
the patient was discharged with decreasing
serum levels of biliburin (although levels were
still high) and continued treatment with
UDCA and prednisolone (30 mg/day; fol-
lowed by a steroid taper). Complete clinical
and liver chemistry recovery (Figure 1) was
performed 2 months later, almost concomi-
tant with treatment interruption. Nine
months after exposure, no further recurrences
had occurred.
Discussion
QpE acts by disrupting acyl lipid biosynthesis
via speciﬁc inhibition of the plastid isoform of
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2007]acetyl-coenzyme A carboxylase (ACCase) in
grasses. This enzyme catalyzes the ﬁrst com-
mitted reaction in fatty acid biosynthesis,
which is virtually ubiquitous in nature.
However, as noted by Price et al. (2003),
“herbicide-binding cooperativity to the
ACCase is the only kinetic property that dif-
ferentiates naturally” or in “selected insensitive
ACCases [found in other monocotyledons,
dicotyledons, or other species such as bacteria
and animals] from the typical sensitive [iso-
form] found in grasses.” 
According to the U.S. EPA (1998), the
acute oral toxicity (lethal dose) of QpE in
rats is estimated at 1,480 and 1,670 mg/kg
for females and males, respectively; dermal
toxicity is > 5,000 mg/kg, and inhalation
toxicity (lethal concentration) is 5.8 mg/L.
In a 90-day feeding study in mice with diets
that contained 0, 100, 316, or 1,000 ppm
(approximately 0, 15, 47.4, and 150 mg/kg/
day, respectively), the no observed effect
level (NOEL) was < 15 mg/kg/day (the low-
est dose tested) on the basis of increased liver
weight and reversible histopathologic effects
in the liver (centrilobular and generalized
hepatocyte enlargement and eosinophilic
changes in animals’ livers) (U.S. EPA 1998).
Toxicity for both short and intermediate
terms was assessed in a 21-day dermal toxic-
ity study in which New Zealand White rab-
bits received 15 dermal applications of QpE
ester (aqueous paste) at 0, 125, 600, or
2,000 mg/kg/day, 6 hr/day, 5 days/week for
3 weeks (U.S. EPA. 1998). No dermal or
systemic toxicity was found; the NOEL was
2,000 mg/kg/day. The U.S. EPA (1998) also
found no maternal or developmental toxicity
after in utero exposure in rats or rabbits.
Neither Mexico nor Canada has maxi-
mum residue limits (MRLs) for QpE.
Compatibility cannot be achieved with the
Canadian negligible residue type limit of
0.1 ppm because data supporting U.S. use
patterns showed real residues > 0.1 ppm
(U.S. EPA 2005). However, the U.S. EPA
(2006) recently proposed a limit for residues
of QpE of 0.05 ppm in or on barley, flax
(seed), and wheat and 2.0 ppm in or on sun-
ﬂower (seed).
It is noteworthy that our literature search
found no reports of serious adverse effects on
humans [data obtained from the National
Library of Medicine (NLM 2006), PubMed
(2007), Toxnet (2006), and the EXtension
TOXicology NETwork (EXTOXNET
2007)].
The patient mentioned that he had
sprayed his crops with QpE 5 months before
his admission without presenting any symp-
toms; however, he used adequate personal
protective equipment to handle the QpE at
that time. The use of protective equipment,
which limited his exposure to the com-
pound, could explain the absence of symp-
toms at that time.
The second time, the patient applied a
mixture of 1 L of 10.3% QpE solution added
to 250 L water. His personal protective
equipment consisted of protective eyewear, a
mechanical ﬁlter respirator, chemical-resistant
gloves, long pants, and shoes plus socks, but
he wore a short-sleeved shirt. During a gust
of wind, a large amount of spray mist came in
contact with the skin on his upper extremities
and neck. Given the fact that he had never
presented symptoms from handling herbi-
cides in the past, he continued his work for
approximately an hour before discarding his
clothing and washing thoroughly with abun-
dant water and soap. Even though the
patient’s description explicitly defined the
exposure route and time, the amount of
chemical could not be estimated.
The recent exposure to QpE in the
absence of other causes of liver disease
increased our suspicion of drug-induced liver
injury (DILI). The patient met all three
Council for International Organizations of
Medical Science laboratory criteria for DILI:
two determinations of ALT plasma concen-
trations > 2 ULN, conjugated bilirubin
> 2 ULN, and combined increases of AST,
ALP, and TBIL with one value > 2 ULN
(Benichou 1990). According to these criteria,
our patient demonstrated an ALT/ALP ratio
of 2.5, which classiﬁed as a mixed hepatocel-
lular and cholestatic liver injury; those with
isolated ALT > 2 ULN or ALT/ALP ratio > 5
are classiﬁed as hepatocellular; cases with an
ALT/ALP ratio < 2 are cholestatic, and cases
with an ALT/ALP ratio between 2 and 5 are
classified as mixed liver injuries (Benichou
1990). Histopathologic features of liver
biopsy, mainly the portal inﬂammatory inﬁl-
tration by neutrophils, lymphocytes, and
eosinophils, as well as intrahepatic cholestasis,
established the diagnosis of DILI (Watkins
and Seeff 2006).
Lee (2003) outlined six possible mecha-
nisms for DILI, and it is important to note
that many of these mechanisms can be
involved in a chemical-induced liver injury.
Chemicals that can damage the structure and
function of the bile canaculi can produce
cholestasis. A key component of bile secretion
Elefsiniotis et al.
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Figure 1. QpE-induced hepatotoxicity shown by a time course of liver biochemistry results for AST, ALT,
ALP, γ-GT, and TBIL.
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Figure 2. QpE-induced hepatotoxicity indicated by (A) Moderate portal inﬂammatory inﬁltrates consisting of
neutrophils, lymphocytes (long arrow), and eosinophils (short arrows), and (B) moderate intralobular
cholestasis (arrows). Slides are stained with hematoxylin and eosin. Bar = 100 µm and applies to (A) and (B).involves a series of ATP-dependant export
pumps such as the canalibular bile salt trans-
porter (Cullen 2005); binding of a chemical
to these transporter molecules results in the
arrest of bile formation or movement within
the lumen of the canalicular system (Trauner
et al. 1998). Secondary injury can result
because bile salts have detergent action that
can damage cell membranes and injure biliary
epithelium or hepatocytes in areas of
cholestasis (Cullen 2005). Another mecha-
nism leading to cholestasis is mediated by
drugs that bind to actin ﬁlaments, resulting
in disruption of the actin ﬁlaments situated
around the bile canaliculi, thus preventing
the normal pulsatile contractions that move
bile through the canalicular system to the bile
ducts (Cullen 2005). One or more of these
mechanisms could possibly explain QpE
cholestatic hepatotoxicity.
In our patient there was evidence of a
drug-induced immunologic disorder. Serology
for positive c-ANCA, elevated levels of
β2-MG, and histology with eosinophil inﬁl-
trates in the hepatic lobule suggest an auto-
immune mechanism of QpE hepatotoxicity.
Adducts can form between drug metabolites
and cellular proteins or nucleic acids and gen-
erate neoantigens. Neoantigens may be
formed on the cell surface by interactions of
chemicals with certain cell membrane recep-
tors, or they may be processed, transported to
the cell surface, and presented as antigens
(Cullen 2005). Depending on the context of
the major histocompatibility complex of anti-
gen presentation, either cellular or humoral
immunity can be involved (Lewis 2000).
Injury can occur through direct cellular
cytotoxicity and antibody-dependent cellu-
lar cytotoxicity. Hepatic injury may be sig-
nificantly exacerbated by recruitment of
inflammatory cells such as neutrophils and
activation of sinusoidal lining cells, particu-
larly Kupffer cells (Jaeschke et al. 2002).
When primed by tumor necrosis factor-α, or
interleukin-1 (IL-1), neutrophils interact
with extracellular ANCA, resulting in their
degranulation and production of reactive
oxygen species that can cause tissue damage.
In addition, ANCA-activated neutrophils
can adhere to, and kill, endothelial cells
in vitro, and can be induced to release pro-
inflammatory cytokines such as IL-1 and
IL-8. ANCA are present in a high percentage
of patients with certain systemic vasculitis syn-
dromes, particularly Wegener’s granulomato-
sis and microscopic polyangiitis (Sneller et al.
2005). Even though anti-LKM and anti-LM
are the most developed autoantibodies in
autoimmune DILI (Watkins and Seeff 2006),
the transient appearance of c-ANCA in our
patient could be attributed to the induction of
immune mechanisms by QpE.
Human leukocyte antigen (HLA) mole-
cules play a critical role in the host immune
response because they are involved in antigen
presentation. Specifically, class II antigens
present foreign antigens to both CD4+
helper-T lymphocytes (Th-1 and Th-2), lead-
ing to both humoral and cell-mediated
immune responses (Delves and Roitt 2000).
Serum β2-MG levels have been anticipated to
represent the turnover of HLA antigens and
are associated with lymphocyte proliferation
and activation (Bjerrum et al. 1987). In
patients with liver disease and without renal
impairment or concomitant hematologic dis-
orders, serum β2-MG represents a non-
speciﬁc marker of lymphocyte activation and
proliferation, resulting in a Th-1–mediated
immune response (Freni et al. 1997). In our
patient, serum β2-MG elevation possibly fol-
lows the drug-induced immunologic reaction
of the host. We postulate that the ﬁrst mini-
mal exposure to the chemical (5 months
before admission) sensitized the patient,
whereas the second exposure (9 days before
admission) triggered the strong immunologic
reaction that resulted in hepatotoxicity. It is
noteworthy that c-ANCA were undetected 2,
3, and 9 months after exposure, and serum
β2-MG levels were normal 9 months after
exposure (2.51 mg/L). Also, the second low
peak in aminotransferase levels, determined
in the 35th week (Figure 1), could be attrib-
uted either to a second late onset of QpE
hepatotoxicity or to steroid treatment (Topal
et al. 2006). The patient was treated with
UDCA, as reported by Watkins and Seeff
(2006). The steroid was initiated 1 week after
admission in an attempt to control the con-
tinuously ascending bilirubin levels, even
though it is not a recommended medication
for immune-mediated liver injury in text-
books of internal medicine (Dienstag and
Isselbacher 2005).
Conclusion
We determined that QpE, an often applied
herbicide, is a probable inducer of occupa-
tional liver injury, according to the World
Health Organization (WHO) deﬁnitions of
adverse drug reactions (WHO 2006).
Causality between the compound and liver
injury is “probable” because a rechallenge pro-
cedure would be unethical. We also demon-
strated the biochemical and histologic patterns
of QpE-induced liver injury, its “signature”
profile, as the pattern of hepatotoxicity was
characterized by Watkins and Seeff (2006).
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